Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 23Carcinoma, Non-Small-Cell Lung 10Colorectal Neoplasms 7Neoplasms 5Neoplasm Metastasis 5Skin Neoplasms 4Lung Neoplasms 4Pancreatic Neoplasms 3Uveal Melanoma 2Triple Negative Breast Neoplasms 2Skin Diseases 2Hereditary Sensory and Autonomic Neuropathies 2Brain Neoplasms 2Thyroid Neoplasms 1Thyroid Diseases 1Spinocerebellar Degenerations 1Solid Tumors Harboring a BRAF V600 Mutation 1Solid Tumors 1Solid Tumor 1Rectal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Noonan Syndrome 5 1Neurofibromatosis 1 1Low-grade Serous Ovarian Cancer 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Glioma 1Gastrointestinal Stromal Tumors 1Fallopian Tube Neoplasms 1

Interventions

binimetinib 2Watchful Waiting 2Aminolevulinic Acid 2palbociclib 1ipatasertib 1exemestane 1encorafenib 1baricitinib 1atezolizumab 1Vemurafenib 1VP-102 1Trabectedin 1Paclitaxel 1Injections, Intradermal 1Gonadotropin-Releasing Hormone 1Everolimus 1Dacarbazine 1Cantharidin 1BF-200 ALA 1Anastrozole 1AZD9833 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Skin Diseases × binimetinib × Clear all
NCT01909453 2026-02-27

COLUMBUS

Pfizer

Phase 3 Completed
921 enrolled 48 charts 1 FDA
Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

NCT01763164 2021-03-22

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Pfizer

Phase 3 Completed
402 enrolled 21 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Skin Diseases, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡